Citigroup Restated “Buy” Rating For Standard Chartered PLC (LON:STAN); 3 Analysts Are Bullish AMAG Pharmaceuticals, Inc. (AMAG) Last Week

In an analyst note released on Monday morning, Standard Chartered PLC (LON:STAN) stock had its “Buy” Rating kept by analysts at Citigroup.

Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 have Buy rating, 1 Sell and 10 Hold. Therefore 21% are positive. AMAG Pharmaceuticals had 36 analyst reports since August 18, 2015 according to SRatingsIntel. The firm has “Hold” rating by Deutsche Bank given on Wednesday, November 4. The firm has “Hold” rating by Cantor Fitzgerald given on Thursday, November 2. The firm has “Outperform” rating by Leerink Swann given on Wednesday, May 4. Jefferies maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) rating on Friday, November 3. Jefferies has “Buy” rating and $16.0 target. As per Thursday, October 27, the company rating was initiated by Needham. As per Tuesday, September 1, the company rating was initiated by Raymond James. As per Wednesday, August 19, the company rating was downgraded by Zacks. Jefferies maintained it with “Buy” rating and $3400 target in Tuesday, June 6 report. The firm has “Market Perform” rating given on Wednesday, May 4 by Raymond James. The firm earned “Buy” rating on Wednesday, August 16 by Jefferies. See AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) latest ratings:

01/02/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0 Maintain
18/01/2018 Broker: Piper Jaffray Rating: Hold New Target: $15.0 Maintain
07/12/2017 Broker: FBR Capital Rating: Hold New Target: $16.0
03/11/2017 Broker: Jefferies Rating: Buy New Target: $16.0 Maintain
03/11/2017 Broker: Morgan Stanley Rating: Overweight Old Target: $26 New Target: $22 Maintain
02/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0 Maintain
23/10/2017 Broker: PiperJaffray Rating: Neutral New Target: $18 Initiates Coverage On
17/10/2017 Broker: Janney Capital Rating: Hold
08/09/2017 Broker: Morgan Stanley Rating: Buy New Target: $26.0 Initiate
16/08/2017 Broker: Jefferies Rating: Buy New Target: $34.0 Maintain

The stock increased 1.50% or GBX 11.8 during the last trading session, reaching GBX 799.9. About 955,827 shares traded. Standard Chartered PLC (LON:STAN) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 29 analysts covering Standard Chartered PLC (LON:STAN), 12 have Buy rating, 11 Sell and 6 Hold. Therefore 41% are positive. Standard Chartered PLC has GBX 1300 highest and GBX 300 lowest target. GBX 645.85’s average target is -19.26% below currents GBX 799.9 stock price. Standard Chartered PLC had 263 analyst reports since July 23, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Nomura given on Monday, August 3. Credit Suisse maintained the shares of STAN in report on Tuesday, March 28 with “Underperform” rating. The firm earned “Neutral” rating on Monday, February 27 by JP Morgan. BNP Paribas maintained Standard Chartered PLC (LON:STAN) rating on Thursday, March 10. BNP Paribas has “Underperform” rating and GBX 385 target. As per Thursday, August 4, the company rating was maintained by JP Morgan. The firm earned “Overweight” rating on Wednesday, April 27 by JP Morgan. The stock of Standard Chartered PLC (LON:STAN) has “Neutral” rating given on Wednesday, August 12 by Nomura. The firm has “Outperform” rating given on Thursday, January 7 by Bernstein. The stock of Standard Chartered PLC (LON:STAN) earned “Buy” rating by Shore Capital on Friday, January 8. The firm earned “Hold” rating on Thursday, February 11 by Deutsche Bank.

Standard Chartered PLC provides various banking services and products in Asia, Africa, and the Middle East. The company has market cap of 26.33 billion GBP. The firm operates in four divisions: Corporate & Institutional Banking, Private Banking, Commercial Banking, and Retail Banking. It has a 999.88 P/E ratio. It offers personal banking services, including savings and accounts; personal, instalment, or revolving loans; mortgages; credit cards; life, savings and retirement planning, health and medical, home, motor, and travel insurance products; investment advisory services; retail FX products; mutual funds; and employee banking services.

Investors sentiment increased to 1.44 in 2017 Q3. Its up 0.35, from 1.09 in 2017Q2. It is positive, as 21 investors sold AMAG Pharmaceuticals, Inc. shares while 43 reduced holdings. 35 funds opened positions while 57 raised stakes. 39.98 million shares or 4.47% less from 41.85 million shares in 2017Q2 were reported. Alps Advsr accumulated 34,752 shares. Great West Life Assurance Co Can accumulated 0% or 48,946 shares. Kamunting Street Cap Management L P invested 0.14% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Thrivent For Lutherans reported 21,500 shares. Panagora Asset Inc owns 220,925 shares. Macquarie Grp Ltd reported 14,400 shares or 0% of all its holdings. Pinebridge Invests L P reported 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Virginia Retirement System Et Al stated it has 0.01% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Sei Investments Co, a Pennsylvania-based fund reported 15,795 shares. 48,000 were accumulated by Employees Retirement Systems Of Texas. Walleye Trading Ltd Liability reported 24,919 shares. Gideon owns 0.21% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 11,725 shares. Falcon Point Cap Limited Liability Company owns 839,477 shares. Zebra Capital Management Llc has 13,332 shares. Quantbot Technology L P stated it has 2,623 shares or 0% of all its holdings.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $458.10 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

Since August 29, 2017, it had 0 insider buys, and 1 insider sale for $20,938 activity. $20,938 worth of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) shares were sold by Vittiglio Joseph.

The stock increased 5.28% or $0.65 during the last trading session, reaching $12.95. About 2.49 million shares traded or 201.26% up from the average. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has risen 3.00% since February 12, 2017 and is uptrending. It has underperformed by 13.70% the S&P500.